SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jaybe who wrote (3969)11/4/2015 1:36:35 PM
From: Biomaven  Read Replies (1) of 4474
 
>>And given what we know to date, I think '788 is likely a next-gen, pan-EGFR inhibitor, addressing all forms (Ex. 19, 20, and 21) of primary and secondary resistance in EGFRm and Her-2+ NSCLC, but would likely be focused, initially, on unmet need of T790M- (negative) population, 45% of frontline EGFR TKI resistance. Her-2+ represents ~30% of this 45% resistant population. There are a few competitors in the pipeline with OR rates ranging from 20-50%.

Yes, I think this is most plausible - fits pretty much everything we know, including the pretty picture they posted.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News